Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV

Inovio Pharmaceuticals, Inc. - INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet's EClinicalMedicine

Immunogenicity of a DNA vaccine candidate for COVID-19

Positive Results from Preclinical Testing Support Clinical Development of COVID-19 DNA Vaccine

Immunogenicity of a DNA vaccine candidate for COVID-19

Immunogenicity of a DNA vaccine candidate for COVID-19

Frontiers Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines

Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development

A brief review on DNA vaccines in the era of COVID-19

Evaluation of a synthetic DNA SARS-CoV-2 vaccine INO-4800 using a nonhuman primate model

COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models - ScienceDirect